| Literature DB >> 27664384 |
Piero Ruscitti1, Paola Cipriani1, Francesco Ciccia2, Francesco Masedu3, Vasiliki Liakouli1, Francesco Carubbi1, Onorina Berardicurti1, Giuliana Guggino2, Paola Di Benedetto1, Salvatore Di Bartolomeo1, Marco Valenti3, Giovanni Triolo2, Roberto Giacomelli4.
Abstract
Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significantly associated with mortality. In conclusion, adult MAS is associated with high mortality rate. Some clinical features at diagnosis may be predictive of MAS-associated death.Entities:
Keywords: Adult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome
Mesh:
Substances:
Year: 2016 PMID: 27664384 DOI: 10.1016/j.autrev.2016.09.016
Source DB: PubMed Journal: Autoimmun Rev ISSN: 1568-9972 Impact factor: 9.754